Edouard Louis
University of Liège
Inflammatory bowel diseaseDiseaseCrohn's diseaseDiabetes mellitusMedicine
What is this?
Publications 425
#1Yoram BouhnikH-Index: 56
#2Edouard LouisH-Index: 63
Last. Laurent Peyrin-BirouletH-Index: 59
view all 3 authors...
Whilst many laboratories take appropriate care, there are still cases where the performances of untargeted profiling methods suffer from a lack of design, control and articulation of the various steps involved. This is particularly harmful to modern comprehensive analytical instrumentations that otherwise provide an unprecedented coverage of complex matrices. In this work, we present a global analytical workflow based on comprehensive two-dimensional gas chromatography (GC×GC) coupled to high re...
#1Angela-Maria Merli (University of Liège)
#2Sophie Vieujean (University of Liège)
Last. Cécile Oury (University of Liège)H-Index: 17
view all 22 authors...
#1Erwin Dreesen (Katholieke Universiteit Leuven)H-Index: 8
#2Filip BaertH-Index: 38
Last. Ann Gils (Katholieke Universiteit Leuven)H-Index: 38
view all 15 authors...
Abstract Background and aims In the TAILORIX trial, no benefit could be shown of infliximab dose escalation based on pharmacokinetic (infliximab serum concentrations) and pharmacodynamic (biomarkers and symptoms) monitoring compared to dose escalation based on symptoms alone in patients with Crohn’s disease (CD). We investigated whether integration of pharmacokinetic and pharmacodynamic monitoring can be used to evaluate responses to infliximab induction and maintenance therapy, based on finding...
4 CitationsSource
#1Guillaume Pineton de Chambrun (University of Montpellier)H-Index: 11
#2Aurelien AmiotH-Index: 20
Last. Laurent Peyrin-BirouletH-Index: 59
view all 19 authors...
Background & Aims It is a challenge to manage patients with ulcerative proctitis (UP) refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a large cohort of patients with refractory UP. Methods We conducted a nationwide retrospective cohort study of 104 consecutive patients with active UP refractory to conventional therapies, treated at 1 of 15 centers in France or 1 center in Belgium (the GETAID cohort). Patients received at least 1 inj...
#2Sophie Allepaerts (University of Liège)H-Index: 4
Last. Edouard Louis (University of Liège)H-Index: 63
view all 4 authors...
#1Lucija Klarić (Edin.: University of Edinburgh)H-Index: 9
#2Yakov A. Tsepilov (NSU: Novosibirsk State University)H-Index: 5
Last. Stuart McGurnaghan (Edin.: University of Edinburgh)H-Index: 6
view all 53 authors...
Effector functions of immunoglobulin G (IgG) are regulated by the composition of a glycan moiety, thus affecting activity of the immune system. Aberrant glycosylation of IgG has been observed in many diseases, but little is understood about the underlying mechanisms. We performed a genome-wide association study of IgG N-glycosylation (N = 8090) and, using a data-driven network approach, suggested how associated loci form a functional network. We confirmed in vitro that knockdown of IKZF1 decreas...
1 CitationsSource
#1Geert R. D'HaensH-Index: 61
#2Orlaith Kelly (Connolly Hospital Blanchardstown)H-Index: 1
Last. Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
view all 28 authors...
Abstract Background & Aims Non-invasive tests to measure endoscopic activity in patients with Crohn’s disease (CD) have limitations. We aimed to develop a test to identify patients in remission, based on endoscopic analysis, and monitor CD activity based on serum levels of proteins. Methods We developed a test to measure 13 proteins in blood (ANG1, ANG2, CRP, SAA1, IL7, EMMPRIN, MMP1, MMP2, MMP3, MMP9, TGFA, CEACAM1, and VCAM1), called the endoscopic healing index [EHI] using samples from 278 pa...
1 CitationsSource
#1Edouard Louis (University of Liège)H-Index: 63
Last. Kerri L. Novak (U of C: University of Calgary)H-Index: 13
view all 17 authors...
Introduction Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, inflammatory bowel diseases (IBD). Each class and type of medication available for the treatment of IBD has distinct characteristics and long-term effects that a patient may consider. We present the results of qualitative research that aimed to develop a descriptive framework that outlines the most relevant disease and/or treatment attributes for IBD treatment decisions and focuses on the patient perspective.